Breaking News

You are here » Indian-Commodity  :  Top News  :  Zydus Cadila receives final approval from USFDA for Oxybutynin Chloride Extended-Release Tablets

28-Jun2017

Zydus Cadila receives final approval from USFDA for Oxybutynin Chloride Extended-Release Tablets

Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg, and 15 mg. The drug is used to treat symptoms of overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. The estimated sale for Oxybutynin Chloride Extended-Release Tablets is $150.9 million.

The group now has more than 120 approvals and has so far filed over 300 ANDAs, since the commencement of the filing process in FY 2003-04.


Related News

View all news

Crude oil futures end higher on Friday

Crude oil futures ended higher on Friday on worries about possible impact of US sanctions on Iran's oil exports on crude supply in the market coupled with potential US-Saudi tensions. Prices also supported......

Crude oil futures extend losses on Thursday

Extending previous session losses, crude oil futures ended lower on Thursday due to a sharp jump in US crude inventories last week and on demand growth concerns. The Energy Information Administration's......

Gold futures end higher on Thursday

Gold futures ended higher on Thursday despite rising US dollar on minutes of the Federal Reserve's latest policy meeting indicating that the central bank is staying the course on interest rate hikes.Gold......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......